Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q1 2019 Results - Earnings Call Transcript

Catabasis Pharmaceuticals, Inc. (CATB) Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM ET

Company Participants

Andrea Matthews - Vice President-Corporate Affairs
Jill Milne - Chief Executive Officer
Joanne Donovan - Chief Medical Officer
Andrew Nichols - Chief Scientific Officer
Noah Clauser - Vice President of Finance

Conference Call Participants

Liana Moussatos - Wedbush Securities, Inc.
Joel Beatty - Citigroup
Hartaj Singh - Oppenheimer & Co., Inc.

Operator

Good day, ladies and gentlemen, and welcome to the Q1 Catabasis Pharmaceuticals Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As reminder, this call may be recorded.

I would now like to introduce your host for today's conference Andrea Matthews. Please go ahead.

Andrea Matthews

Thank you, Chris. Welcome to today's Catabasis Pharmaceuticals conference call, where we'll provide a corporate update and review our first quarter 2019 financial results. With me today are: Jill Milne, Chief Executive Officer; Joanne Donovan, Chief Medical Officer; Andrew Nichols, Chief Scientific Officer; and Noah Clauser, Vice President of Finance.

We issued a press release this morning, summarizing our corporate update and our Q1 2019 financial results, which we will reference on today's call and is available on our website. I would like to note that during today's call, we will make statements related to our business based on current and future expectations that may be considered forward-looking statements under federal securities laws.

Actual results may differ materially from those indicated by these statements as a result of a variety of risks and uncertainties, including those discussed in our most recent Quarterly Report on Form 10-Q, which we filed this morning with the SEC and is also available on our website. Such statements represent our judgment as